Physician profile
Fredric Mintz
NPI 1194759530
$8,098.07
in general payments reported to CMS, 2019-2025
45 companies · $1,133 in 2025
The $1,133 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,118 · 2020: $1,208 · 2021: $1,342 · 2022: $1,136 · 2023: $948 · 2024: $1,213 · 2025: $1,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,293.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,444.79 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $953.50 | 2019-2025 | |
| Novo Nordisk INC | $724.51 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $531.33 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Pfizer INC. | $386.04 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $377.71 | 2020-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $320.12 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Eisai INC. | $312.92 | 2020-2025 | |
| Glaxosmithkline, LLC. | $301.39 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Allergan, INC. | $252.33 | 2019-2020 | |
| Amarin Pharma, INC. | $217.22 | 2019-2022 | |
| Amgen INC. | $198.84 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $180.69 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $179.87 | 2019-2022 | |
| Indivior INC. | $171.78 | 2019-2025 | Sublocade |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fredric Mintz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.